Successful use of anti-IL-23 molecules in overweight-to-obese psoriatic patients: A multicentric retrospective study.
BMI
anti-IL23
psoriasis
Journal
Dermatologic therapy
ISSN: 1529-8019
Titre abrégé: Dermatol Ther
Pays: United States
ID NLM: 9700070
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
revised:
09
08
2022
received:
22
06
2022
accepted:
26
08
2022
pubmed:
30
8
2022
medline:
5
11
2022
entrez:
29
8
2022
Statut:
ppublish
Résumé
Advances in treatment with biological agents have changed the course of psoriasis. However observational reports and controlled trials draw attention to the heterogeneity of treatment response and point out that Body Mass index (BMI) may be a key factor for therapy efficacy. Therefore, we investigated the impact of BMI on the efficacy of the most recent biological molecules (anti IL-23 inhibitors) to improve patient care management. A bicentric retrospective study was performed to assess efficacy and safety of guselkumab, risankizumab and tildrakizumab in overweight-to-obese patients with moderate to-severe psoriasis up to 52 weeks of treatment. This study involved 113 patients classified according to BMI as overweight or obese. The clinical response to treatment was assessed by Psoriasis Area and Severity Index (PASI) at week 0, 24 and 52. Across all anti-IL-23 treatments, mean PASI score was ≤2 (1.1) after 6 months of treatment and decreased under 1 after 12 months in all groups. No severe adverse events, death or malignancy cases were recorded. Our results suggest that overweight or obesity does not influence therapeutic response in psoriatic patients treated with anti-IL-23 antagonists. Therefore, therapeutic strategies with this mechanism of action would be more suitable for high BMI patients.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e15793Informations de copyright
© 2022 Wiley Periodicals LLC.
Références
Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80:1029-1072.
Puig L. Obesity and psoriasis: body weight and body mass index influence the response to biological treatment. J Eur AcadDermatol Venereol. 2011;25:1007-1011.
Lebwohl M, Yeilding N, Szapary P, et al. Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: rationale for dosing recommendations. J Am Acad Dermatol. 2010;63:571-579.
Clark L, Lebwohl M. The effect of weight on the efficacy of biologic therapy in patients with psoriasis. J Am Acad Dermatol. 2008;58:443-446.
Carrascosa JM, Vilavella M, Garcia-Doval I, et al. Body mass index in patients with moderate-to-severe psoriasis in Spain and its impact as an independent risk factor for therapy withdrawal: results of the Biobadaderm Registry. J Eur Acad Dermatol Venereol. 2014;28:907-914.
Papp KA, Reich K, Blauvelt A, et al. Efficacy of tildrakizumab for moderate- to-severe plaque psoriasis: pooled analysis of three randomized controlled trials at weeks 12 and 28. J Eur Acad Dermatol Venereol. 2019;33:1098-1106.
Edson-Heredia E, Sterling K, Alatorre C, et al. Heterogeneity of response to biologic treatment: perspective for psoriasis. J Investig Dermatol. 2014;134:18-23.
Al-Mutairi N, Nour T. The effect of weight reduction on treatment outcomes in obese patients with psoriasis on biologic therapy: a randomized controlled prospective trial. Exp Opin Biol Ther. 2014;14:749-756.
Summary of product characteristics. https://www.ema.europa.eu/en/documents/product-information/stelara-epar-product-information_en.pdf .